GSK plc
GSK
$51.84
-$0.53-1.01%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 59.54% | 3,696.29% | 30.27% | 54.21% | 21.95% |
| Total Depreciation and Amortization | -423.43% | -19.59% | 92.06% | 48.89% | -50.66% |
| Total Amortization of Deferred Charges | 8.28% | -- | -- | -- | 7.16% |
| Total Other Non-Cash Items | -14.02% | 89.97% | 75.56% | 424.46% | 305.44% |
| Change in Net Operating Assets | 188.24% | -130.51% | -37.79% | -129.08% | -128.73% |
| Cash from Operations | 1.58% | 6.89% | 99.42% | 18.71% | -24.87% |
| Capital Expenditure | -9.39% | -5.66% | 10.24% | 16.70% | -15.40% |
| Sale of Property, Plant, and Equipment | -77.87% | 418.10% | 164.73% | -0.67% | 798.43% |
| Cash Acquisitions | 31.30% | -22,178.29% | 90.37% | -10.47% | -3,250.75% |
| Divestitures | 120.77% | 134.54% | -323.57% | 66.89% | 26.36% |
| Other Investing Activities | 39.27% | 9.70% | -132.72% | -116.05% | -177.19% |
| Cash from Investing | 13.41% | -117.02% | -185.95% | -662.59% | -530.47% |
| Total Debt Issued | -58.84% | -- | -- | -- | 195.17% |
| Total Debt Repaid | 93.15% | 89.74% | -163.76% | 43.16% | 18.23% |
| Issuance of Common Stock | -- | -100.00% | 100.00% | -33.33% | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -9.62% | -10.05% | -6.54% | -7.02% | -11.08% |
| Other Financing Activities | -3.35% | -724.00% | 31.75% | -20.00% | -102.91% |
| Cash from Financing | -5.58% | -9.89% | -58.57% | 180.40% | 75.83% |
| Foreign Exchange rate Adjustments | -708.27% | 279.81% | -244.15% | 42.50% | 121.23% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 24.07% | -492.92% | -437.33% | 411.95% | 338.65% |